A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

PURPOSE: Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single‐agent pazopanib in patients with MPM. MATERIALS AND METHODS: Patients with MPM who...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Parikh, Kaushal, Mandrekar, Sumithra J., Allen‐Ziegler, Katie, Esplin, Brandt, Tan, Angelina D., Marchello, Benjamin, Adjei, Alex A., Molina, Julian R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2019
Gaiak:
Lung Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288653/
https://ncbi.nlm.nih.gov/pubmed/31872928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0574
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak